| Literature DB >> 21267058 |
Ashly D Black1, Josip Car, Claudia Pagliari, Chantelle Anandan, Kathrin Cresswell, Tomislav Bokun, Brian McKinstry, Rob Procter, Azeem Majeed, Aziz Sheikh.
Abstract
BACKGROUND: There is considerable international interest in exploiting the potential of digital solutions to enhance the quality and safety of health care. Implementations of transformative eHealth technologies are underway globally, often at very considerable cost. In order to assess the impact of eHealth solutions on the quality and safety of health care, and to inform policy decisions on eHealth deployments, we undertook a systematic review of systematic reviews assessing the effectiveness and consequences of various eHealth technologies on the quality and safety of care. METHODS ANDEntities:
Mesh:
Year: 2011 PMID: 21267058 PMCID: PMC3022523 DOI: 10.1371/journal.pmed.1000387
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Figure 1PRISMA flow diagram.
Critical appraisal of “reviews” (see legend for description of quality assessment criteria).
| Lead Author and Year | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Q12 | Q13 | Q14 | Q15 | Totala |
| Ammenwerth 2008 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 24 |
| Anderson 1997 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 1 | 2 | 23 |
| Balas 2004 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 22 |
| Bennett 2003 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 18 |
| Bryan 2008 | 1 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 19 |
| Charvet-Protat 1998 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 12 |
| Chatellier 1998 | 2 | 2 | 2 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 21 |
| Chaudhry 2006 | 1 | 1 | 2 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 18 |
| Clamp 2005 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 17 |
| Delpierre 2004 | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 13 |
| Dexheimer 2008 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 2 | 1 | 0 | 0 | 19 |
| Durieux 2008 | 2 | 2 | 1 | 2 | 2 | 1 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 23 |
| Eslami 2007 | 2 | 2 | 1 | 1 | 0 | 1 | 2 | 2 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 18 |
| Eslami 2008 | 2 | 2 | 1 | 1 | 0 | 1 | 2 | 2 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 18 |
| Eslami 2009 | 2 | 2 | 1 | 0 | 1 | 2 | 2 | 0 | 1 | 0 | 0 | 2 | 1 | 1 | 1 | 16 |
| Fitzmaurice 1998 | 2 | 1 | 0 | 2 | 2 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 12 |
| Garg 2005 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 20 |
| Georgiou 2007 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 1 | 0 | 2 | 1 | 2 | 1 | 21 |
| Hayward 2009 | 2 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 2 | 1 | 0 | 2 | 1 | 1 | 1 | 15 |
| Hender 2000 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Heselmans 2009 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 22 |
| Hider 2002 | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 21 |
| Irani 2009 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 18 |
| Jamal 2009 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 16 |
| Jerant 2000 | 1 | 2 | 0 | 0 | 2 | 1 | 1 | 1 | 2 | 1 | 0 | 2 | 1 | 1 | 1 | 16 |
| Kaushal 2003 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 16 |
| Mador 2009 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 20 |
| Mitchell 2001 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 17 |
| Montgomery 1998 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 14 |
| Niazkhani 2009 | 2 | 2 | 2 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 22 |
| Oren 2003 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 2 | 2 | 14 |
| Pearson 2009 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 23 |
| Poissant 2005 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 25 |
| Randell 2007 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 17 |
| Reckmann 2009 | 2 | 2 | 1 | 2 | 0 | 2 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 2 | 2 | 20 |
| Rothschild 2004 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 2 | 1 | 0 | 2 | 1 | 1 | 1 | 16 |
| Schedlbauer 2009 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 22 |
| Shachak 2009 | 2 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 15 |
| Shamliyan 2008 | 1 | 2 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 13 |
| Shebl 2007 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 17 |
| Shekelle 2006 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 2 | 1 | 20 |
| Shekelle 2009 | 1 | 1 | 2 | 1 | 0 | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 21 |
| Shiffman 1999 | 1 | 1 | 2 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 14 |
| Shojania 2009 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 22 |
| Sintchenko 2007 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 17 |
| Smith 2007 | 1 | 2 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 2 | 1 | 17 |
| Tan 2005 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 19 |
| Thompson 2009 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 9 |
| Uslu 2008 | 2 | 1 | 0 | 0 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 16 |
| van Rosse 2009 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 0 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 24 |
| Wolfstadt 2008 | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 13 |
| Wong 2010 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 22 |
| Yourman 2008 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum total score of 30, each question (or Q) having a maximum of 2 points, refer to Table S1 for the critical appraisal form for additional details.
Evidence of benefits associated with EHRs.
| Benefits | |||||||
| Review ID | Data Security | Legibility | Accessibility | Completeness | Comprehensiveness | Efficiency | Secondary Uses |
| Clamp 2005 | N/A | + | + | + | N/A | +/- | N/A |
| Irani 2009 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Jamal 2009 | N/A | N/A | N/A | +/++ | N/A | + | N/A |
| Mador 2009 | N/A | N/A | ++ | N/A | N/A | +/- | +/- |
| Mitchell 2001 | +/- | + | N/A | + | + | +/+ + | N/A |
| Poissant 2005 | N/A | N/A | N/A | N/A | N/A | +/+ + | N/A |
| Shachak 2009 | N/A | N/A | N/A | + | +/++ | N/A | N/A |
| Shekelle 2006 | N/A | + | N/A | + | + | +/+ + | N/A |
| Shekelle 2009 | N/A | N/A | N/A | N/A | N/A | +/- | + |
| Thompson 2009 | N/A | N/A | N/A | N/A | N/A | + | N/A |
| Uslu 2008 | N/A | + | + | N/A | N/A | ++ | N/A |
Evidence of benefits: N/A, not assessed; +/-, none; +, weak; +/++, weak to moderate; ++, moderate.
Evidence of risks associated with EHRs.
| Risks | |||||
| Review ID | Paper Persistence | Patient Disengagement | Insecure Data | Increased Time | Increased Costs |
| Clamp 2005 | N/A | - | N/A | - | - |
| Irani 2009 | N/A | +/- | N/A | N/A | N/A |
| Jamal 2009 | N/A | N/A | N/A | +/- | +/- |
| Mador 2009 | N/A | N/A | N/A | - | N/A |
| Mitchell 2001 | N/A | - | - | - | - |
| Poissant 2005 | N/A | N/A | N/A | - - | N/A |
| Shachak 2009 | - | -/- - | N/A | N/A | N/A |
| Shekelle 2006 | N/A | N/A | N/A | - | - |
| Shekelle 2009 | N/A | N/A | N/A | - | - |
| Thompson 2009 | N/A | N/A | N/A | +/- | N/A |
| Uslu 2008 | N/A | N/A | N/A | N/A | +/- |
Evidence of risks: N/A, not assessed; +/-, none; -, weak; -/- -, weak to moderate; --, moderate.
Evidence of benefits associated with PACS.
| Benefits | ||||||
| Review ID | Data Integrity | Image Resolution | Image Access | Cost Savings | Time Savings | Diagnostic Accuracy |
| Anderson 1997 | + | +/- | + | +/- | + | +/- |
| Charvet-Protat 1998 | + | N/A | + | + | + | N/A |
| Clamp 2005 | + | N/A | + | +/- | + | + |
Evidence of benefits: N/A, not assessed; +/-, none; +, weak; +/++, weak to moderate; ++, moderate.
Evidence of benefits associated with PACS.
| Risks | ||||
| Review ID | Film Persistence | Record Loss | Increased Time | Increased Costs |
| Anderson 1997 | +/- | +/- | +/- | - |
| Charvet-Protat 1998 | N/A | N/A | +/- | - |
| Clamp 2005 | N/A | N/A | +/- | - |
Evidence of risks: N/A, not assessed; +/-, none; -, weak; -/- -, weak to moderate; --, moderate.
Evidence of benefits associated with CPOE.
| Benefits | |||||
| Review ID | Resource Utilisation | Indicated Care | Patient Outcomes | Cost Savings | Time Savings |
| Chaudry 2006 | +/+ + | +/++ | +/- | +/- | +/- |
| Garg 2005 | +/+ + | +/++ | +/- | + | N/A |
| Georgiou 2007 | +/- | + | +/- | + | +/- |
| Jamal 2009 | + | + | +/- | N/A | N/A |
| Niyazkhani 2009 | N/A | + | N/A | N/A | +/+ + |
| Poissant 2005 | N/A | N/A | N/A | N/A | +/+ + |
| Rothschild 2004 | +/+ + | + | +/- | + | + |
| Shekelle 2006 | +/+ + | +/++ | +/- | + | + |
Evidence of benefits: N/A, not assessed; +/-, none; +, weak; +/++, weak to moderate; ++, moderate.
Evidence of risks associated with CPOE.
| Risks | ||||
| Review ID | Increased Time | Interruptions | Increased Costs | Workarounds |
| Chaudry 2006 | +/- | N/A | +/- | N/A |
| Garg 2005 | N/A | - | +/- | N/A |
| Georgiou 2007 | - | N/A | +/- | N/A |
| Jamal 2009 | N/A | N/A | N/A | N/A |
| Niyazkhani 2009 | - | -- | +/- | - |
| Poissant 2005 | - - | - | N/A | N/A |
| Rothschild 2004 | +/- | N/A | +/- | N/A |
| Shekelle 2006 | +/- | N/A | +/- | N/A |
Evidence of risks: N/A, not assessed; +/-, none; -, weak; -/- -, weak to moderate; --, moderate.
Evidence of benefits associated with ePrescribing.
| Benefits | |||||||
| Reference ID | Surrogate Outcomes | Guideline Adherence | Safer Prescribing | Communication | Patient Outcomes | Resource/Cost Savings | Time Savings |
| Ammenwerth 2008 | Pot. ADEs +/+ + | N/A | MEs ++ | N/A | ADEs + | N/A | N/A |
| Bryan 2008 | + | + | N/A | N/A | +/- | + | N/A |
| Chatellier 1998 | +/++ | N/A | ++/+ | N/A | Death +/-Haemorrhage +/-Thromboembolic events +/- | N/A | N/A |
| Clamp 2005 | ++ | + | MEs ++ | + | ADEs + | + | + |
| Delpierre 2004 | +/- | + | MEs+ | N/A | +/- | N/A | N/A |
| Duriex 2008 | +/++ | + | +/++ | N/A | Death +/- | +/++ | N/A |
| Eslami 2007 | + | +/+ + | +/- | N/A | +/- | + | + |
| Eslami 2008 | + | +/+ + | + | + | +/- | + | + |
| Eslami 2009 | + | + | N/A | N/A | +/- | N/A | N/A |
| Fitzmaurice 1998 | + | N/A | + | N/A | + | N/A | N/A |
| Garg 2005 | +/++ | + | +/- | N/A | +/- | +/- | N/A |
| Hider 2002 | +/++ | +/+ + | + | +/+ + | + | + | N/A |
| Jamal 2009 | + | +/++ | + | N/A | +/- | + | N/A |
| Mitchell 2001 | + | N/A | N/A | N/A | +/- | + | + |
| Mollon 2009 | +/++ | N/A | N/A | N/A | +/- | +/- | N/A |
| Niyazkhani 2009 | + | N/A | N/A | +/++ | N/A | N/A | +/++ |
| Poissant 2005 | N/A | N/A | N/A | N/A | N/A | N/A | +/- |
| Rothschild 2004 | +/++ | + | MEs ++ | N/A | ADEs + | + | + |
| Schedlbauer 2009 | +/++ | + | MEs ++ | N/A | Renal ADEs+Falls+ | + | N/A |
| Shamliyan 2008 | + | N/A | MEs ++ | N/A | ADEs + | N/A | N/A |
| Shekelle 2006 | +/+ + | N/A | MEs + | N/A | ADEs + | +/- | N/A |
| Shiffman 1999 | N/A | +/+ + | N/A | N/A | +/- | N/A | N/A |
| Shojania 2009 | + | + | N/A | N/A | + | N/A | N/A |
| Sintchenko 2007 | ++ | + | N/A | N/A | Death +/-ADEs + | N/A | N/A |
| Tan 2005 | + | N/A | MEs + | N/A | +/- | +/- | + |
| Van Rosse 2009 | +/+ + | N/A | ++ | + | Death +/-ADEs +/- | N/A | + |
| Wolfstadt 2008 | N/A | N/A | N/A | N/A | ADEs +/- | N/A | N/A |
| Yourman 2008 | + | + | N/A | N/A | +/- | +/- | N/A |
Evidence of benefits: N/A, not assessed; +/-, none; +, weak; +/++, weak to moderate; ++, moderate.
Evidence of risks associated with ePrescribing.
| Risks | |||
| Reference ID | Patient Harm | Increased Time | Increased Costs |
| Ammenwerth 2008 | +/- | N/A | N/A |
| Bryan 2008 | +/- | N/A | N/A |
| Chatellier 1998 | +/- | N/A | N/A |
| Clamp 2005 | +/- | - | +/- |
| Delpierre 2004 | +/- | N/A | N/A |
| Durieux 2008 | +/- | N/A | +/- |
| Eslami 2007 | +/- | -/- - | - |
| Eslami 2008 | +/- | -/- - | - |
| Eslami 2009 | +/- | N/A | N/A |
| Fitzmaurice 1998 | N/A | N/A | N/A |
| Garg 2005 | +/- | N/A | N/A |
| Hider 2002 | +/- | N/A | N/A |
| Jamal 2009 | +/- | N/A | N/A |
| Mitchell 2001 | +/- | +/- | +/- |
| Mollon 2009 | +/- | N/A | +/- |
| Niyazkhani 2009 | N/A | -/-- | N/A |
| Poissant 2005 | N/A | -/- - | N/A |
| Rothschild 2004 | N/A | +/- | +/- |
| Schedlbauer 2009 | +/- | N/A | +/- |
| Shamliyan 2008 | +/- | N/A | N/A |
| Shekelle 2006 | +/- | N/A | +/- |
| Shiffman 1999 | +/- | N/A | N/A |
| Shojania 2009 | +/- | N/A | N/A |
| Sintchenko 2007 | +/- | N/A | N/A |
| Tan 2005 | N/A | +/- | +/- |
| Van Rosse 2009 | +/- | +/- | N/A |
| Wolfstadt 2008 | N/A | N/A | N/A |
| Yourman 2008 | N/A | N/A | +/- |
Evidence of risks: N/A, not assessed; +/-, none; -, weak; -/- -, weak to moderate; --, moderate.
Evidence of benefits associated with CDSS.
| Benefits | ||||
| Reference ID | Indicated Care | Guideline Adherence | Surrogate Outcomes | Patient Outcomes |
| Balas 2004 | + | ++ | +/++ | +/- |
| Bryan 2008 | + | + | + | +/- |
| Chaudhry 2006 | + | ++ | + | +/- |
| Delpierre 2004 | ++ | +/- | + | +/- |
| Dexheimer, 2008 | ++ | + | + | +/- |
| Garg 2005 | +/++ | ++ | +/++ | +/- |
| Hayward 2009 | +/- | N/A | +/- | +/- |
| Heselmans 2009 | N/A | +/- | +/- | +/- |
| Jamal 2009 | +/++ | ++ | + | +/- |
| Jerant, 2000 | ++ | + | + | +/- |
| Montgomery 1998 | + | N/A | + | +/- |
| Randell 2007 | +/- | +/- | +/- | +/- |
| Shekelle 2006 | ++ | ++ | +/++ | +/- |
| Shiffman 1999 | + | +/++ | + | +/- |
| Shojania 2009 | +/++ | ++ |
| +/- |
| Sintchenko 2007 | + | + | +/++ | +/- |
| Smith 2007 | N/A | N/A | +/- | +/- |
| Tan 2009 | +/- | N/A | +/- | +/- |
Evidence of benefits: N/A, not assessed; +/-, none; +, weak; +/++, weak to moderate; ++, moderate.
Evidence of risks associated with CDSS.
| Risks | ||
| Reference ID | Practitioner performance | Patient outcomes |
| Balas 2004 | N/A | +/- |
| Bryan 2008 | N/A | +/- |
| Chaudhry 2006 | N/A | +/- |
| Delpierre 2004 | +/- | +/- |
| Dexheimer, 2008 | N/A | +/- |
| Garg 2005 | N/A | +/- |
| Hayward 2009 | N/A | +/- |
| Heselmans 2009 | N/A | N/A |
| Jamal 2009 | +/- | +/- |
| Jerant, 2000 | +/- | +/- |
| Montgomery 1998 | +/- | - |
| Randell 2007 | - | +/- |
| Shekelle 2006 | N/A | +/- |
| Shiffman 1999 | +/- | +/- |
| Shojania 2009 | N/A | +/- |
| Sintchenko 2007 | +/- | +/- |
| Smith 2007 | N/A | +/- |
| Tan 2009 | +/- | +/- |
Evidence of risks: N/A, not assessed; +/-, none; -, weak; -/- -, weak to moderate; --, moderate.